Innoviva
INVA Small CapHealthcare · Biotechnology
Aggiornato: May 2, 2026, 22:05 UTC
Metriche Chiave
Analisi della Valutazione
Informazioni sull'Azienda
Innoviva Stock at a Glance
Innoviva (INVA) is currently trading at 19,71 € with a market capitalization of 1,5 Mrd. €. The trailing P/E ratio stands at 7x, with a forward P/E of 10.46x. The 52-week range spans from 14,09 € to 21,45 €; the current price is 8.1% below the yearly high. Year-over-year revenue growth stands at +24.8%. The net profit margin stands at 65.92%.
💰 Dividendo
Innoviva currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Raccomandazioni degli Analisti
5 analysts rate Innoviva (INVA) on consensus: None. The average price target is 28,32 €, implying +43.66% from the current price. Analyst price targets range from 15,35 € to 39,24 €.
Tesi di Investimento: Punti di Forza e Debolezze
- Strong revenue growth of 24.8% YoY
- Profitable with 65.92% net margin
- High return on equity (29.09% ROE)
- High gross margin of 74.94% — indicates pricing power
- Currently flagged as undervalued
- Solid balance sheet with low debt (D/E 28.24)
- Positive free cash flow
- –High short interest (12.23%)
Panoramica Tecnica
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profilo di Rischio
The data points to relatively defensive market behavior, elevated short interest (12.23%).
Dati di Trading
Azioni Correlate nello Stesso Settore
Where can I buy Innoviva?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
